Endometrial CancerPhase 3NCT00002976
Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer
A Phase 3 study testing conjugated estrogens in people with Endometrial Cancer, run by Gynecologic Oncology Group at 149 sites in United States.
Trial summary
RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Endometrial Cancer
- What is being tested?
- conjugated estrogens
- How many people
- 2,108 participants
- Where
- 149 sitesUnited States
- Study dates
- Jun 1997to Jul 2006
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed grade I, II or III endometrial adenocarcinoma (endometrioid, villoglandular, mucinous, adenosquamous, papillary serous, clear cell, or not otherwise specified)
- Must have had total hysterectomy and bilateral salpingo-oophorectomy within past 20 weeks
- Surgical stage IA, IB, IC, IIA (occult), or IIB (occult) disease
- Must have had normal mammogram, or a negative breast biopsy after an abnormal mammogram, within past year
PATIENT CHARACTERISTICS:
Age:
- Not specified
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Bilirubin no greater than 1.5 times normal
- SGOT no greater than 3 times normal
- No acute liver disease
Renal:
- Not specified
Cardiovascular:
- No prior thromboembolic disease
Other:
- No prior or current carcinoma of the breast
- No other prior invasive malignancy within the past 5 years except nonmelanoma skin cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Not specified
Endocrine therapy:
- No concurrent hormonal therapy
Radiotherapy:
- Not specified
Surgery:
- See Disease Characteristics
- Recovered from prior surgery
Other:
- No prior cancer treatment that would preclude study therapy
- Concurrent participation on GOG Lap-1 or GOG Lap-2 allowed
Trial locations and contacts
149 sites in 1 country.
149 sites in 1 country
United States149 sites
Abington Memorial Hospital
Abington, Pennsylvania, 19001-3788
Cancer Center of Albany Medical Center
Albany, New York, 12208
Veterans Affairs Medical Center - Albuquerque
Albuquerque, New Mexico, 87108-5138
MBCCOP - University of New Mexico HSC
Albuquerque, New Mexico, 87131
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0912
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
Earl K. Long Medical Center
Baton Rouge, Louisiana, 70805
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Veterans Affairs Medical Center - Biloxi
Biloxi, Mississippi, 39531-2410
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, 35294-3300
Boston Medical Center
Boston, Massachusetts, 02118
State University of New York Health Science Center at Brooklyn
Brooklyn, New York, 11203
Fletcher Allen Health Care - Medical Center Campus
Burlington, Vermont, 05401
Cooper Hospital/University Medical Center
Camden, New Jersey, 08103-1489
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
Veterans Affairs Medical Center - Charleston
Charleston, South Carolina, 29401-5799
Medical University of South Carolina
Charleston, South Carolina, 29425-0721
Cancer Center at the University of Virginia
Charlottesville, Virginia, 22908
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, 60611-3013
MBCCOP - University of Illinois at Chicago
Chicago, Illinois, 60612-7323
Veterans Affairs Medical Center - Chicago (Westside Hospital)
Chicago, Illinois, 60612
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
Veterans Affairs Medical Center - Cincinnati
Cincinnati, Ohio, 45220-2288
Barrett Cancer Center
Cincinnati, Ohio, 45267-0501
Ireland Cancer Center
Cleveland, Ohio, 44106
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195-9001
Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, 65203
CCOP - Columbus
Columbus, Ohio, 43206
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210-1240
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Central Illinois
Decatur, Illinois, 62526
University of Colorado Cancer Center
Denver, Colorado, 80010
Veterans Affairs Medical Center - Denver
Denver, Colorado, 80220
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309-1016
Veterans Affairs Medical Center - Detroit
Detroit, Michigan, 48201-1932
Henry Ford Hospital
Detroit, Michigan, 48202
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
CCOP - Duluth
Duluth, Minnesota, 55805
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
Dwight David Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234-6200
University of Texas Medical Branch
Galveston, Texas, 77555-0587
Butterworth Hospital
Grand Rapids, Michigan, 49503
CCOP - Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, 49503
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, 54301
CCOP - Greenville
Greenville, South Carolina, 29615
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
Hines, Illinois, 60141
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813-2424
Tripler Army Medical Center
Honolulu, Hawaii, 96859-5000
CCOP - M.D. Anderson Research Base
Houston, Texas, 77030-4009
Indiana University Cancer Center
Indianapolis, Indiana, 46202-5289
Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242-1009
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
Veterans Affairs Medical Center - Jackson
Jackson, Mississippi, 39216
Mayo Clinic
Jacksonville, Florida, 32224
Veterans Affairs Medical Center - Boston (Jamaica Plain)
Jamaica Plain, Massachusetts, 02130
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
University of Kansas Medical Center
Kansas City, Kansas, 66160-7390
Veterans Affairs Medical Center - Kansas City
Kansas City, Missouri, 64128
CCOP - Kansas City
Kansas City, Missouri, 64131
Keesler Medical Center - Keesler AFB
Keesler Air Force Base, Mississippi, 39534-2576
CCOP - Dayton
Kettering, Ohio, 45429
Baptist Regional Cancer Center - Knoxville
Knoxville, Tennessee, 37901
University of Tennessee Medical Center at Knoxville
Knoxville, Tennessee, 37920
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40502-2236
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Veterans Affairs Medical Center - Little Rock (McClellan)
Little Rock, Arkansas, 72205
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
Veterans Affairs Medical Center - West Los Angeles
Los Angeles, California, 90073
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
Community Hospital of Los Gatos
Los Gatos, California, 95032
Covenant Health System
Lubbock, Texas, 79410
Veterans Affairs Outpatient Clinic - Martinez
Martinez, California, 94553
Loyola University Medical Center
Maywood, Illinois, 60153
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455
MBCCOP - Gulf Coast
Mobile, Alabama, 36688
Morristown Memorial Hospital
Morristown, New Jersey, 07962-1956
Brookview Research, Inc.
Nashville, Tennessee, 37203
Study site
New Britain, Connecticut, 06052
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
Tulane University School of Medicine
New Orleans, Louisiana, 70112
Ochsner Clinic
New Orleans, Louisiana, 70121
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021
Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Eastern Virginia Medical School
Norfolk, Virginia, 23510-1115
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, 73104
Veterans Affairs Medical Center - Oklahoma City
Oklahoma City, Oklahoma, 73104
University of Oklahoma College of Medicine
Oklahoma City, Oklahoma, 73190
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Methodist Cancer Center - Omaha
Omaha, Nebraska, 68114
Chao Family Comprehensive Cancer Center
Orange, California, 92868
Sacred Heart Hospital of Pensacola
Pensacola, Florida, 32504
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
CCOP - Greater Phoenix
Phoenix, Arizona, 85006-2726
Veterans Affairs Medical Center - Phoenix (Carl T. Hayden)
Phoenix, Arizona, 85012
Veterans Affairs Medical Center - Portland
Portland, Oregon, 97207
Good Samaritan Hospital Comprehensive Cancer Center
Portland, Oregon, 97210
CCOP - Columbia River Program
Portland, Oregon, 97225
OHSU Cancer Institute
Portland, Oregon, 97239
Massey Cancer Center
Richmond, Virginia, 23298-0037
University of Virginia at Roanoke
Roanoke, Virginia, 24013
University of Rochester Medical Center
Rochester, New York, 14642
CCOP - Beaumont
Royal Oak, Michigan, 48073-6769
University of California Davis Medical Center
Sacramento, California, 95817
Huntsman Cancer Institute
Salt Lake City, Utah, 84112-5550
Veterans Affairs Medical Center - Salt Lake City
Salt Lake City, Utah, 84148
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78284-7845
Veterans Affairs Medical Center - San Antonio (Murphy)
San Antonio, Texas, 78284
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
Medical College of Georgia Comprehensive Cancer Center
Savannah, Georgia, 31403-3089
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101
Swedish Cancer Institute
Seattle, Washington, 98104
Veterans Affairs Medical Center - Seattle
Seattle, Washington, 98108
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109-1024
Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana, 71130-3932
Veterans Affairs Medical Center - Shreveport
Shreveport, Louisiana, 71130
CCOP - Sioux Community Cancer Consortium
Sioux Falls, South Dakota, 57104
Southern Pines Women's Health Center
Southern Pines, North Carolina, 28388-0749
Providence Hospital - Southfield
Southfield, Michigan, 48075-9975
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807
St. Louis University Health Sciences Center
St Louis, Missouri, 63110
Washington University School of Medicine
St Louis, Missouri, 63110
Department of OB-GYN
St Louis, Missouri, 63117
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141
Tampa Bay Cancer Consortium
St. Petersburg, Florida, 33701
State University of New York Health Sciences Center - Stony Brook
Stony Brook, New York, 11794-8091
Crouse Hospital
Syracuse, New York, 13210
CCOP - Northwest
Tacoma, Washington, 98405-0986
Madigan Army Medical Center
Tacoma, Washington, 98431-5000
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612-9497
Veterans Affairs Medical Center - Temple
Temple, Texas, 76504
CCOP - Scott and White Hospital
Temple, Texas, 76508
David Grant Medical Center
Travis Air Force Base, California, 94535
Veterans Affairs Medical Center - Tucson
Tucson, Arizona, 85723
Arizona Cancer Center
Tucson, Arizona, 85724
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
MBCCOP-Howard University Cancer Center
Washington D.C., District of Columbia, 20060
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307-5001
CCOP - Wichita
Wichita, Kansas, 67214-3882
Veterans Affairs Medical Center - Wichita
Wichita, Kansas, 67218
CCOP - Southeast Cancer Control Consortium
Winston-Salem, North Carolina, 27104-4241
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, 27157-1065
University of Tennessee Cancer Institute
Winston-Salem, North Carolina, 27157-1065
CCOP - MainLine Health
Wynnewood, Pennsylvania, 19096
About this study
Official title: A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma
RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence.
PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer.
Read the detailed description
OBJECTIVES:
- Determine the effect of estrogen replacement therapy on recurrence free and overall survival in women with a history of stage I or II endometrial adenocarcinoma.
OUTLINE: This is a randomized, double blind study. Patients are stratified according to stage of endometrial cancer (IA vs IB/IC vs II). Patients are randomized to one of two treatment arms:
- Arm I: Patients receive oral conjugated estrogens (Premarin) daily for 3 years.
- Arm II: Patients receive oral placebo daily for 3 years. Patients are followed every 6 months for 3 years and then annually for 2 years.
PROJECTED ACCRUAL: Approximately 2,108 patients will be accrued for this study.
- Conditions
- Endometrial Cancer
- Being tested
- conjugated estrogens
- Keywords
- stage I endometrial carcinoma, stage II endometrial carcinoma, endometrial adenocarcinoma
- Medical subject headings
- Endometrial Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
conjugated estrogensDrug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startJun 1997
- Primary completionJul 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Endometrial CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Enrolment
- 2,108 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gynecologic Oncology Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), Eastern Cooperative Oncology Group, SWOG Cancer Research Network
- Investigators
- Richard R. Barakat, MD, Study chair, Memorial Sloan Kettering Cancer CenterScott Wadler, MD, Study chair, Albert Einstein College of MedicineDavid S. Alberts, MD, Study chair, University of Arizona
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00002976
- Sponsor's protocol ID
- CDR0000065498
- Other IDs
- GOG-137A, E-G0137, SWOG-G0137
- Status last verified
- Apr 2003
- First submitted
- 1 Nov 1999
- Last updated
- 11 Apr 2013
- Results posted
- No
Publications
Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS; Gynecologic Oncology Group Study. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Feb 1;24(4):587-92. doi: 10.1200/JCO.2005.02.8464.
PubMed 16446331
Study at a glance
From the registry record, last updated by the sponsor on 11 Apr 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma
- ClinicalTrials.gov ID
- NCT00002976
- Acronym / sponsor ID
- CDR0000065498
- Conditions
- Endometrial Cancer
- Keywords
- stage I endometrial carcinoma, stage II endometrial carcinoma, endometrial adenocarcinoma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 2,108 participants (estimated)
- Lead sponsor
- Gynecologic Oncology GroupResearch network
- Collaborators
- National Cancer Institute (NCI), Eastern Cooperative Oncology Group, SWOG Cancer Research Network
- Study start
- Jun 1997
- Primary completion
- Jul 2006 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence.
PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer.
Detailed description
OBJECTIVES:
- Determine the effect of estrogen replacement therapy on recurrence free and overall survival in women with a history of stage I or II endometrial adenocarcinoma.
OUTLINE: This is a randomized, double blind study. Patients are stratified according to stage of endometrial cancer (IA vs IB/IC vs II). Patients are randomized to one of two treatment arms:
- Arm I: Patients receive oral conjugated estrogens (Premarin) daily for 3 years.
- Arm II: Patients receive oral placebo daily for 3 years. Patients are followed every 6 months for 3 years and then annually for 2 years.
PROJECTED ACCRUAL: Approximately 2,108 patients will be accrued for this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| conjugated estrogens | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Apr 2013.
- Results publication: PubMed 16446331Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS; Gynecologic Oncology Group Study. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Feb 1;24(4):587-92. doi: 10.1200/JCO.2005.02.8464.
Related trials for Endometrial Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Active, not recruitingPhase 3
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
Endometrial Cancer
RecruitingPhase 3
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Richard R. Barakat, MD study chair
Memorial Sloan Kettering Cancer Center
Scott Wadler, MD study chair
Albert Einstein College of Medicine
David S. Alberts, MD study chair
University of Arizona
149 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing conjugated estrogens in people with Endometrial Cancer, run by Gynecologic Oncology Group at 149 sites in United States.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 11 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 149 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00002976, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Apr 2013.